Gout in the UK and Germany: Prevalence, comorbidities and management in general practice 2000-2005

Annals of the Rheumatic Diseases

Volumn 67, Issue 7, 2008, Pages 960-966

  Annemans, L ^a,b,c,f   Spaepen, E ^a   Gaskin, M ^a   Bonnemaire, M ^d   Malier, V ^d   Gilbert, T ^d   Nuki, G ^e  

^a IQVIA   (United States)

^b GHENT UNIVERSITY   (Belgium)

^c FREE UNIVERSITY OF BRUSSELS   (Belgium)

^d IPSEN   (France)

^e UNIVERSITY OF EDINBURGH   (United Kingdom)

^f GHENT UNIVERSITY   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOPURINOL; ANTIRHEUMATIC AGENT; BENZBROMARONE; COLCHICINE; CORTICOSTEROID DERIVATIVE; CYCLOOXYGENASE 2 INHIBITOR; DIURETIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; PROBENECID; SULFINPYRAZONE; URIC ACID;

ADULT; AGED; ARTICLE; COMORBIDITY; COMPARATIVE STUDY; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE EXACERBATION; FEMALE; GENERAL PRACTICE; GERMANY; GOUT; HEALTH CARE MANAGEMENT; HUMAN; MAJOR CLINICAL STUDY; MALE; OBESITY; PREVALENCE; PRIORITY JOURNAL; UNITED KINGDOM; URIC ACID BLOOD LEVEL;

AGED; ALLOPURINOL; DRUG ADMINISTRATION SCHEDULE; DRUG MONITORING; EPIDEMIOLOGIC METHODS; FAMILY PRACTICE; FEMALE; GERMANY; GOUT; GOUT SUPPRESSANTS; GREAT BRITAIN; HUMANS; MALE; MIDDLE AGED; RECURRENCE; URIC ACID;

EID: 46849088805     PISSN: 00034967     EISSN: None     Source Type: Journal    
DOI: 10.1136/ard.2007.076232     Document Type: Article

References (32)

1. Sarawate CA, Patel PA, Schumacher HR, Yang W, Brewer KK, Bakst AW. Serum urate levels and gout flares: analysis from managed care data. J Clin Rheumatol 2006;12:61-5.
2. Campion EW, Glynn RJ, DeLabry LO. Asymptomatic hyperuricemia. Risks and conseguences in the Normative Aging Study. Am J Med 1987;82:421-6.
3. Becker MA, Schumacher HR Jr, Wortmann RL, MacDonald PA, Eustace D, Palo WA, et al. Febuxostat compared with allopurinol in patients with hyperuricemia and gout. N Engl J Med 2005;353:2450-61.
4. Perez-Ruiz F, Calabozo M, Pijoan JI, Herrero-Beites AM, Ruibal A. Effect of uratelowering therapy on the velocity of size reduction of tophi in chronic gout. Arthritis Rheum 2002;47:356-60.
5. Monu JU, Pope TL Jr. Gout: a clinical and radiologic review. Radiol Clin North Am 2004;42:169-84.
6. Zhang W, Doherty M, Pascual E, Bardin T, Barskova V, Conaghan P, et al. EULAR evidence based recommendations for gout - Part I Diagnosis: Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 2006;65:1301-11.
7. Zhang W, Doherty M, Bardin T, Pascual E, Barskova V, Conaghan P, et al. EULAR evidence based recommendations for gout - Part II Management: Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 2006;65:1312-24.
8. Li-Yu J, Clayburne G, Sieck M, Beutler A, Rull M, Eisner E, et al. Treatment of chronic gout. Can we determine when urate stores are depleted enough to prevent attacks of gout? J Rheumatol 2001;28:577-80.
9. Shoji A, Yamanaka H, Kamatani N. A retrospective study of the relationship between serum urate level and recurrent attacks of gouty arthritis: evidence for reduction of recurrent gouty arthritis with antihyperuricemic therapy. Arthritis Rheum 2004;51:321-5.
10. Mikuls TR, Farrar JT, Bilker WB, Fernandes S, Schumacher HR Jr, Saag KG. Gout epidemiology: results ftom the UK General Practice Research Database, 1990-1999. Ann Rheum Dis 2005;64:267-72.
11. Peterson AM, Nau DP, Cramer JA, Benner J, Gwadry-Sridhar F, Nichol M. A checklist for medication compliance and persistence studies using retrospective databases. Value Health 2007;10:3-12. Available at http://www.ispor.org/workpaper/MedComplianceChecklist. asp#Measurement_of_Compliance (accessed 20 March 2008).
12. Harris CM, Lloyd DC, Lewis J. The prevalence and prophylaxis of gout in England. J Clin Epidemiol 1995;48:1153-8.
13. Currie WJ. Prevalence and incidence of the diagnosis of gout in Great Britain. Ann Rheum Dis 1979;38:101-6.
14. Adams PF, Hendershot GE, Marano MA. Current estimates from the National Health Interview Survey, 1996. National Center for Health Statistics. Vital Health Stat 10 1999;(200):1-2003.
15. Wallace KL, Riedel AA, Joseph-Ridge N, Wortmann R. Increasing prevalence of gout and hyperuricemia over 10 years among older adults in a managed care population. J Rheumatol 2004;31:1582-7.
16. Roubenoff R. Gout and hyperuricemia. Rheum Dis Clin North Am 1990;16:539-50.
17. Symmons D, Turner G, Webb R, Asten P, Barrett E, Lunt M, et al. The prevalence of rheumatoid arthritis in the United Kingdom: new estimates for a new century. Rheumatology (Oxford) 2002;41:793- 800.
18. World Health Organization. The SuRF Report 2. Surveillance of chronic disease risk factors. WHO: Geneva 2005 Available at http://www.heartstats.org/temp/Tabsp11.14spweb07.xls (accessed 120 March 2008).
19. International Diabetes Federation. (2003) The diabetes atlas.2nd ed. Brussels: International Diabetes Federation, 2003. http://www.heartstats.org/temp/ESspTabsp11.2spweb05.xls (accessed 20 March 2008).
20. Brochner-Mortensen K. One hundred gouty patients. Acta Med Scand 1941;106:81-107.
21. Grahame R, Scott JT. Clinical survey of 354 patients with gout. Ann Rheum Dis 1970;29:461-8.
22. Choi HK, Ford ES, Li C, Curhan G. Prevalence of the metabolic syndrome in patients with gout: the Third National Health and Nutrition Examination Survey. Arthritis Rheum 2007;57:109-15.
23. Riedel AA, Nelson M, Wallace K, Joseph-Ridge N, Cleary M, Fam AG. Prevalence of comorbid conditions and prescription medication use among patients with gout and hyperuricaemia in a managed care setting. J Clin Rheumatol 2004;10:308-14.
24. Johnson RJ, Kang DH, Feig D, Kivlighn S, Kanellis J, Watanabe S, et al. Is there a pathogenetic role for uric acid in hypertension and cardiovascular and renal disease? Hypertension 2003;41:1183-90.
25. Krishnan E, Baker JF, Furst DE, Schumacher HR. Gout and the risk of acute myocardial infarction. Arthritis Rheum 2006;54:2688-96.
26. Choi HK, Atkinson K, Karlson EW, Curhan G. Obesity, weight change, hypertension, diuretic use, and risk of gout in men: the health professionals follow-up study. Arch Intern Med 2005;165:742-8.
27. Jordan KM, Cameron S, Snaith M. British Society for Rheumatology and British health professionals in rheumatology guideline for the management of gout. Rheumatology (Oxford) (in press).
28. Choi HK, Mount DB, Reginato AM. Pathogenesis of gout. Ann Intern Med 2005;143:499-516.
29. Janssens HJ, van de Lisdonk EH, Janssen M, van den Hoogen HJ, Verbeek AL. Gout, not induced by diuretics? A case-control study from primary care. Ann Rheum Dis 2006;65:1080-3.
30. Perez-Ruiz F, Alonso-Ruiz A, Calabozo M, Herrero-Beites A, Garcia-Erauskin G, Ruiz-Lucea E. Efficacy of allopurinol and benzbromarone for the control of hyperuricaemia. A pathogenic approach to the treatment of primary chronic gout. Ann Rheum Dis 1998;57:545-9.
31. Pascual E. Persistence of monosodium urate crystals and low-grade inflammation in the synovial fluid of patients with untreated gout. Arthritis Rheum 1991;34:141-5
32. Hande KR, Noone RM, Stone WJ. Severe allopurinol toxicity. Description and guidelines for prevention in patients with renal insufficiency. Am J Med 1984;76:47-56.